387 related articles for article (PubMed ID: 9816175)
21. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
[TBL] [Abstract][Full Text] [Related]
22. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
Garcia JA; Mekhail T; Elson P; Wood L; Bukowski RM; Dreicer R; Rini BI
BJU Int; 2012 Jan; 109(1):63-9. PubMed ID: 21244601
[TBL] [Abstract][Full Text] [Related]
24. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
25. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
26. Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients.
Roth MD; Gitlitz BJ; Kiertscher SM; Park AN; Mendenhall M; Moldawer N; Figlin RA
Cancer Res; 2000 Apr; 60(7):1934-41. PubMed ID: 10766183
[TBL] [Abstract][Full Text] [Related]
27. Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes.
Suzuki H; Katayama N; Ikuta Y; Mukai K; Fujieda A; Mitani H; Araki H; Miyashita H; Hoshino N; Nishikawa H; Nishii K; Minami N; Shiku H
Am J Hematol; 2004 Apr; 75(4):179-89. PubMed ID: 15054806
[TBL] [Abstract][Full Text] [Related]
28. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
[TBL] [Abstract][Full Text] [Related]
29. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
Vallera DA; Taylor PA; Aukerman SL; Blazar BR
Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923
[TBL] [Abstract][Full Text] [Related]
30. Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
Janik JE; Miller LL; Kopp WC; Taub DD; Dawson H; Stevens D; Kostboth P; Curti BD; Conlon KC; Dunn BK; Donegan SE; Ullrich R; Alvord WG; Gause BL; Longo DL
Clin Immunol; 1999 Dec; 93(3):209-21. PubMed ID: 10600331
[TBL] [Abstract][Full Text] [Related]
31. [Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors].
Berthaud P; Eugène-Jolchine I; Spielmann M; Le Chevalier T; Tursz T
Bull Cancer; 1993 May; 80(5):418-30. PubMed ID: 8173195
[TBL] [Abstract][Full Text] [Related]
32. Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: a phase ib clinical study.
Herrmann F; Schulz G; Lindemann A; Meyenburg W; Oster W; Krumwieh D; Mertelsmann R
Behring Inst Mitt; 1988 Aug; (83):107-18. PubMed ID: 2467645
[TBL] [Abstract][Full Text] [Related]
33. Dexamethasone up-regulates granulocyte-macrophage colony-stimulating factor receptor expression on human monocytes.
Hawrylowicz CM; Guida L; Paleolog E
Immunology; 1994 Oct; 83(2):274-80. PubMed ID: 7835947
[TBL] [Abstract][Full Text] [Related]
34. Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor.
Blanchard DK; Serbousek D; Djeu JY
Cancer Res; 1989 Sep; 49(18):5037-43. PubMed ID: 2670200
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.
Whitehead RP; Friedman KD; Clark DA; Pagani K; Rapp L
Clin Cancer Res; 1995 Oct; 1(10):1145-52. PubMed ID: 9815906
[TBL] [Abstract][Full Text] [Related]
36. Granulocyte macrophage colony-stimulating factor expression in human herpetic stromal keratitis: implications for the role of neutrophils in HSK.
Duan R; Remeijer L; van Dun JM; Osterhaus AD; Verjans GM
Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):277-84. PubMed ID: 17197544
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
[TBL] [Abstract][Full Text] [Related]
38. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases.
Anderson PM; Markovic SN; Sloan JA; Clawson ML; Wylam M; Arndt CA; Smithson WA; Burch P; Gornet M; Rahman E
Clin Cancer Res; 1999 Sep; 5(9):2316-23. PubMed ID: 10499599
[TBL] [Abstract][Full Text] [Related]
39. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.
Meropol NJ; Porter M; Blumenson LE; Lindemann MJ; Perez RP; Vaickus L; Loewen GM; Creaven PJ; Wilkes KA; Giedlin MA; Caligiuri MA
Clin Cancer Res; 1996 Apr; 2(4):669-77. PubMed ID: 9816217
[TBL] [Abstract][Full Text] [Related]
40. Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma.
Flohé S; Lendemans S; Selbach C; Waydhas C; Ackermann M; Schade FU; Kreuzfelder E
Crit Care Med; 2003 Oct; 31(10):2462-9. PubMed ID: 14530752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
